TIGHTLINE DEVELOPMENT

Tightline Development specializes in orthopaedic osteotomes, which are surgical tools used for cutting or reshaping bone during procedures. Their product line includes both reusable and single-use osteotome blades, such as the Exodus Revision, which is designed specifically for bone preparation in revision surgeries. These devices are tailored for orthopaedic applications where precise bone modification is required.

Tightline Development is based in the United States. Since their devices are manufactured domestically, they are subject to U.S. regulatory requirements, including classification under the FDA’s regulatory framework. The company’s products are listed in the FDA’s Unique Device Identifier (UDI) database, ensuring traceability and compliance with U.S. medical device regulations.

Tightline Development’s devices, such as their orthopaedic osteotomes, are classified as Class I under regulatory frameworks. This classification is typically assigned to low-risk devices where general controls are sufficient to ensure safety and effectiveness. Since these tools are used in controlled surgical environments with established procedures, they do not require additional pre-market approvals beyond standard compliance measures. The classification helps streamline regulatory oversight while maintaining patient safety.

Yes, Tightline Development’s devices are listed in the FDA’s Unique Device Identifier (UDI) database. This means each product has a standardized identifier that improves traceability, reduces medical errors, and supports supply chain transparency. For healthcare providers, this listing ensures they can verify the device’s authenticity, compliance status, and recall history if needed, enhancing patient safety and operational efficiency.